Highbridge Capital Management LLC Invests $1.18 Million in TriSalus Life Sciences, Inc. (NASDAQ:TLSI)

Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences, Inc. (NASDAQ:TLSI) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 214,545 shares of the company’s stock, valued at approximately $1,184,000. Highbridge Capital Management LLC owned about 0.79% of TriSalus Life Sciences at the end of the most recent quarter.

Separately, Wolverine Asset Management LLC purchased a new position in shares of TriSalus Life Sciences during the 2nd quarter worth $240,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Trading Down 0.9 %

Shares of TLSI stock opened at $4.62 on Thursday. The stock has a fifty day simple moving average of $5.44 and a two-hundred day simple moving average of $7.37. TriSalus Life Sciences, Inc. has a 52-week low of $3.32 and a 52-week high of $10.42.

TriSalus Life Sciences (NASDAQ:TLSI) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.21) earnings per share for the quarter. The firm had revenue of $7.36 million during the quarter.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the company. Canaccord Genuity Group restated a “buy” rating and issued a $12.00 price objective on shares of TriSalus Life Sciences in a research note on Thursday, June 27th. Oppenheimer started coverage on TriSalus Life Sciences in a research note on Monday. They issued an “outperform” rating and a $10.00 price objective on the stock. Finally, Canaccord Genuity Group started coverage on TriSalus Life Sciences in a research note on Thursday, May 30th. They set a “buy” rating and a $12.00 price objective for the company.

Insider Buying and Selling at TriSalus Life Sciences

In related news, CEO Mary T. Szela bought 7,520 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was purchased at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the completion of the transaction, the chief executive officer now owns 377,382 shares in the company, valued at $1,962,386.40. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 76.20% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.